Searched for: in-biosketch:true
person:segevd01
HOPE in action: A prospective multicenter pilot study of liver transplantation from donors with HIV to recipients with HIV
Durand, Christine M; Florman, Sander; Motter, Jennifer D; Brown, Diane; Ostrander, Darin; Yu, Sile; Liang, Tao; Werbel, William A; Cameron, Andrew; Ottmann, Shane; Hamilton, James P; Redd, Andrew D; Bowring, Mary G; Eby, Yolanda; Fernandez, Reinaldo E; Doby, Brianna; Labo, Nazzarena; Whitby, Denise; Miley, Wendell; Friedman-Moraco, Rachel; Turgeon, Nicole; Price, Jennifer C; Chin-Hong, Peter; Stock, Peter; Stosor, Valentina; Kirchner, Varvara A; Pruett, Timothy; Wojciechowski, David; Elias, Nahel; Wolfe, Cameron; Quinn, Thomas C; Odim, Jonah; Morsheimer, Megan; Mehta, Sapna A; Rana, Meenakshi M; Huprikar, Shirish; Massie, Allan; Tobian, Aaron A R; Segev, Dorry L
Liver transplantation (LT) from donors-with-HIV to recipients-with-HIV (HIV D+/R+) is permitted under the HOPE Act. There are only three international single-case reports of HIV D+/R+ LT, each with limited follow-up. We performed a prospective multicenter pilot study comparing HIV D+/R+ to donors-without-HIV to recipients-with-HIV (HIV D-/R+) LT. We quantified patient survival, graft survival, rejection, serious adverse events (SAEs), human immunodeficiency virus (HIV) breakthrough, infections, and malignancies, using Cox and negative binomial regression with inverse probability of treatment weighting. Between March 2016-July 2019, there were 45 LTs (8 simultaneous liver-kidney) at 9 centers: 24 HIV D+/R+, 21 HIV D-/R+ (10 D- were false-positive). The median follow-up time was 23 months. Median recipient CD4 was 287 cells/µL with 100% on antiretroviral therapy; 56% were hepatitis C virus (HCV)-seropositive, 13% HCV-viremic. Weighted 1-year survival was 83.3% versus 100.0% in D+ versus D- groups (p = .04). There were no differences in one-year graft survival (96.0% vs. 100.0%), rejection (10.8% vs. 18.2%), HIV breakthrough (8% vs. 10%), or SAEs (all p > .05). HIV D+/R+ had more opportunistic infections, infectious hospitalizations, and cancer. In this multicenter pilot study of HIV D+/R+ LT, patient and graft survival were better than historical cohorts, however, a potential increase in infections and cancer merits further investigation.
PMID: 34741800
ISSN: 1600-6143
CID: 5116832
Frailty, Age, and Postdialysis Recovery Time in a Population New to Hemodialysis
Fitzpatrick, Jessica; Sozio, Stephen M; Jaar, Bernard G; Estrella, Michelle M; Segev, Dorry L; Shafi, Tariq; Monroy-Trujillo, Jose M; Parekh, Rulan S; McAdams-DeMarco, Mara A
BACKGROUND:Frailty, a phenotype characterized by decreased physiologic reserve and the inability to recover following confrontation with a stressor like hemodialysis, may help identify which patients on incident hemodialysis will experience longer postdialysis recovery times. Recovery time is associated with downstream outcomes, including quality of life and mortality. We characterized postdialysis recovery times among patients new to hemodialysis and quantified the association between frailty and hemodialysis recovery time. METHODS:Among 285 patients on hemodialysis enrolled in the Predictors of Arrhythmic and Cardiovascular Risk in End Stage Renal Disease (PACE) study, frailty was measured using the Fried phenotype. Self-reported recovery time was obtained by telephone interview. We estimated the association of frailty (intermediately frail and frail versus nonfrail) and postdialysis recovery time using adjusted negative binomial regression. RESULTS:Median time between dialysis initiation and study enrollment was 3.4 months (IQR, 2.7-4.9), and that between initiation and recovery time assessment was 11 months (IQR, 9.3-15). Mean age was 55 years, 24% were >65 years, and 73% were Black; 72% of individuals recovered in ≤1 hour, 20% recovered in 1-6 hours, 5% required 6-12 hours to recover, and <5% required >12 hours to recover. Those with intermediate frailty, frailty, and age ≤65 years had 2.56-fold (95% CI, 1.45 to 4.52), 1.72-fold (95% CI, 1.03 to 2.89), and 2.35-fold (95% CI, 1.44 to 3.85) risks, respectively, of longer recovery time independent of demographic characteristics, comorbidity, and dialysis-related factors. CONCLUSIONS:In adults new to hemodialysis, frailty was independently associated with prolonged postdialysis recovery. Future studies should assess the effect of frailty-targeted interventions on recovery time to improve clinical outcomes.
PMCID:8786133
PMID: 35373112
ISSN: 2641-7650
CID: 5806462
When One Size Does Not Fit All: Geographically Heterogeneous Liver Distribution [Meeting Abstract]
Mankowski, M. A.; Gentry, S.; Segev, D.; Trichakis, N.
ISI:000705310103116
ISSN: 1600-6135
CID: 5486632
Kidney Transplantation Confers Survival Benefit for Candidates With Pulmonary Hypertension
Nguyen, Michelle C; Po-Yu Chiang, Teresa; Massie, Allan B; Bae, Sunjae; Motter, Jennifer D; Brennan, Daniel C; Desai, Niraj M; Segev, Dorry L; Garonzik-Wang, Jacqueline M
UNLABELLED:Kidney transplantation (KT) is controversial in patients with pretransplant pulmonary hypertension (PtPH). We aimed to quantify post-KT graft and patient survival as well as survival benefit in recipients with PtPH. METHODS/UNASSIGNED:Using UR Renal Data System (2000-2018), we studied 90 819 adult KT recipients. Delayed graft function, death-censored graft failure, and mortality were compared between recipients with and without PtPH using inverse probability weighted logistic and Cox regression. Survival benefit of KT was determined using stochastic matching and stabilized inverse probability treatment Cox regression. RESULTS/UNASSIGNED: < 0.01) compared with those who remained on the waitlist. CONCLUSIONS/UNASSIGNED:Although PtPH is associated with inferior post-KT outcomes, KT is associated with better survival compared with remaining on the waitlist. Therefore, KT is a viable treatment modality for appropriately selected patients with PtPH.
PMCID:9276173
PMID: 35836668
ISSN: 2373-8731
CID: 5387052
Insights From Transplant Professionals on the Use of Social Media: Implications and Responsibilities
Sandal, Shaifali; Soin, Arvinder; Dor, Frank J M F; Muller, Elmi; Ali, Ala; Tong, Allison; Chan, Albert; Segev, Dorry L; Levan, Macey
PMCID:8842268
PMID: 35185368
ISSN: 1432-2277
CID: 5185282
Delirium Among Adults Undergoing Solid Organ Transplantation
Chu, Nadia M; Segev, Dorry L; McAdams-DeMarco, Mara A
Purpose of Review/UNASSIGNED:To summarize the research on post-operative delirium among patients undergoing solid organ transplantation in efforts to improve recognition, evaluation, and management, as well as highlight areas for future research. Recent Findings/UNASSIGNED:Delirium is a common complication in patients with organ failure before and after undergoing solid organ transplant (range: 4.7-47%). However, it is frequently unrecognized and underdiagnosed-even among those closely monitored after major surgery-given that its manifestation is often variable and inconsistent. Delirium has multifactorial etiologies comprising of a complex mix of predisposing recipient, donor, and transplant factors, as well as intraoperative and perioperative factors. Evidence suggests that delirium risk increases with presence of a greater number of such risk factors, and can lead to adverse outcomes such as increased hospital length of stay, time in the ICU, time on mechanical ventilators, graft dysfunction, graft loss, and mortality. Though no trials have been conducted among transplant populations specifically, delirium has been shown to be preventable among hospitalized older adults generally. Multicomponent, primary prevention strategies designed to target multiple risk factors of delirium, such as cognitive impairment, sleep deprivation, immobility, visual impairment, hearing impairment, and dehydration, have been identified as most effective. Whether these approaches translate to improvements in quality of life and long-term health outcomes among patients with organ failure before and after transplantation is yet to be determined. Summary/UNASSIGNED:Delirium is an important, common, yet potentially preventable complication among patients with organ failure. Future studies are needed to test the efficacy of multicomponent, primary prevention strategies on long-term health outcomes among these vulnerable populations.
PMCID:8936706
PMID: 35321347
ISSN: 2196-3029
CID: 5182462
FRAILTY AND KIDNEY TRANSPLANTATION: A SYSTEMATIC REVIEW AND META-ANALYSIS [Meeting Abstract]
Quint, Evelien; Zogaj, Donika; Banning, Wiesje; Benjamens, Stan; Annema, Coby; Bakker, Stephan; Nieuwenhuijs-Moeke, Gertrude; Segev, Dorry; Mcadams-Demarco, Mara; Pol, Robert
ISI:000689725500292
ISSN: 0934-0874
CID: 5133212
Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases [Letter]
Connolly, Caoilfhionn M.; Ruddy, Jake A.; Boyarsky, Brian J.; Avery, Robin K.; Werbel, William A.; Segev, Dorry L.; Garonzik-Wang, Jacqueline; Paik, Julie J.
ISI:000675434700039
ISSN: 0003-4967
CID: 5133122
DYNAMIC PREDICTION OF KIDNEY GRAFT SURVIVAL WITH ARTIFICIAL INTELLIGENCE: AN INTERNATIONAL STUDY OF DEEP COHORTS OF KIDNEY RECIPIENTS [Meeting Abstract]
Raynaud, Marc; Aubert, Olivier; Reese, Peter; Kamar, Nassim; Chin, Chen-Shan; Bailly, Elodie; Ladriere, Marc; Le Quintrec, Moglie; Delahousse, Michel; Juric, Ivana; Basic-Jukic, Nikolina; Crespo, Marta; Silva Junior, Helio Tedesco; Linhares, Kamilla; de Castro, Maria Cristina Ribeiro; Gervacio, Soler Pujol; Yoo, Daniel; Empana, Jean-Philippe; Ulloa, Camilo; Akalin, Enver; Boehmig, Georg; Huang, Edmund; Glotz, Denis; Jordan, Stanley; Bentall, Andrew; Montgomery, Robert; Oberbauer, Rainer; Segev, Dorry; Friedewald, John; Legendre, Christophe; Jouven, Xavier; Lefaucheur, Carmen; Loupy, Alexandre
ISI:000689725500008
ISSN: 0934-0874
CID: 5133202
EARLY SAFETY OF SARS-CoV-2 MRNA VACCINES IN SOLID ORGAN TRANSPLANT RECIPIENTS [Meeting Abstract]
Ou, Michael; Boyarsky, Brian; Motter, Jennifer; Greenberg, Ross; Teles, Aura; Ruddy, Jake; Krach, Michelle; Werbel, William; Avery, Robin K.; Massie, Allan; Segev, Dorry; Garonzik-Wang, Jacqueline
ISI:000689725500549
ISSN: 0934-0874
CID: 5133222